Table 3.

Hazard ratios (95% CIs) of incident sepsis as a function of baseline fibroblast growth factor 23 concentrations stratified by sex, race, age, and presence or absence of CKD

MeasureQuartile 1 (<53 RU/ml)Quartile 2 (53–70 RU/ml)Quartile 3 (70.1–101 RU/ml)Quartile 4 (>101 RU/ml)Per Doubling of FGF23P Value for Interaction
Women0.93
N82122125169498
 Events364985170340
 Model 1aReference1.08 (0.61 to 1.91)1.74 (1.01 to 2.99)2.32 (1.38 to 3.91)1.35 (1.18 to 1.56)
 Model 2bReference0.99 (0.52 to 1.92)1.17 (0.60 to 2.25)1.36 (0.74 to 2.51)1.17 (0.97 to 1.39)
 Model 3cReference0.98 (0.48 to 1.98)1.08 (0.51 to 2.30)0.97 (0.46 to 2.02)1.02 (0.81 to 1.29)
Men
N15113311891493
 Events716996127363
 Model 1aReference1.04 (0.65 to 1.67)1.42 (0.91 to 2.22)2.72 (1.66 to 4.46)1.51 (1.22 to 1.87)
 Model 2bReference0.98 (0.58 to 1.64)1.39 (0.84 to 2.29)2.49 (1.41 to 4.39)1.45 (1.14 to 1.83)
 Model 3cReference0.73 (0.42 to 1.28)0.94 (0.54 to 1.65)1.19 (0.61 to 2.32)0.96 (0.70 to 1.30)
Black0.38
N134120128115497
 Events41425393229
 Model 1aReference1.38 (0.79 to 2.44)1.35 (0.79 to 2.29)3.65 (2.12 to 6.29)1.39 (1.19 to 1.63)
 Model 2bReference1.26 (0.68 to 2.34)1.14 (0.62 to 2.08)2.99 (1.59 to 5.65)1.20 (0.99 to 1.46)
 Model 3cReference1.04 (0.54 to 1.98)0.76 (0.37 to 1.58)1.99 (0.98 to 4.02)1.32 (1.03 to 1.70)
White
N99135115145494
 Events6676128204474
 Model 1aReference0.94 (0.59 to 1.49)1.63 (1.03 to 2.56)1.98 (1.27 to 3.09)1.36 (1.14 to 1.61)
 Model 2bReference0.88 (0.53 to 1.46)1.41 (0.85 to 2.35)1.43 (0.85 to 2.39)1.33 (1.12 to 1.56)
 Model 3cReference0.74 (0.43 to 1.28)1.17 (0.67 to 2.03)0.79 (0.44 to 1.45)0.95 (0.76 to 1.19)
Age ≥690.44
N79105119155458
 Events385997150344
 Model 1aReference1.22 (0.69 to 2.17)1.83 (1.06 to 3.16)2.43 (1.39 to 4.21)1.51 (1.22 to 1.87)
 Model 2bReference0.94 (0.54 to 1.64)1.43 (0.86 to 2.37)1.76 (1.02 to 3.02)1.13 (0.95 to 1.35)
 Model 3cReference0.85 (0.47 to 1.55)1.04 (0.57 to 1.89)1.02 (0.52 to 1.99)0.92 (0.72 to 1.17)
Age <69
N154150124105533
 Events695984147359
 Model 1aReference1.08 (0.68 to 1.72)1.55 (0.98 to 2.44)2.81 (1.78 to 4.43)1.31 (1.14 to 1.51)
 Model 2bReference0.98 (0.53 to 1.81)1.41 (0.77 to 2.59)1.71 (0.93 to 3.14)1.39 (1.13 to 1.73)
 Model 3cReference0.67 (0.34 to 1.32)0.88 (0.45 to 1.72)0.84 (0.41 to 1.70)1.20 (0.93 to 1.55)
CKDd0.84
N224056101219
 Events252864140257
 Model 1aReference0.90 (0.37 to 2.21)1.19 (0.53 to 2.69)1.61 (0.78 to 3.34)1.19 (0.97 to 1.46)
 Model 2bReference0.75 (0.28 to 2.03)1.04 (0.41 to 2.64)1.37 (0.57 to 3.26)1.19 (0.93 to 1.51)
 Model 3cReference0.80 (0.28 to 2.31)0.77 (0.27 to 2.20)0.83 (0.28 to 2.45)0.96 (0.69 to 1.33)
No CKD
N198207171149725
 Events7885105140408
 Model 1aReference1.13 (0.75 to 1.73)1.58 (1.04 to 2.39)2.09 (1.34 to 3.27)1.38 (1.14 to 1.67)
 Model 2bReference1.01 (0.64 to 1.59)1.36 (0.88 to 2.12)1.57 (0.97 to 2.52)1.16 (0.94 to 1.43)
 Model 3cReference0.85 (0.54 to 1.36)1.07 (0.66 to 1.73)1.04 (0.62 to 1.76)1.01 (0.82 to 1.26)
  • a Model 1 is adjusted for age (except for age-stratified models), sex (except for sex-stratified models), race (except for race-stratified models), region of recruitment, annual family income, and educational attainment.

  • b Model 2 is adjusted for variables in model 2 plus current smoking, body mass index, diabetes status, physical activity, and chronic pulmonary disease status.

  • c Model 3 is adjusted for variables in model 3 and eGFR, log-transformed urine albumin-creatinine ratio, and log-transformed high-sensitivity C-reactive protein.

  • d CKD defined as an eGFR <60 ml/min per 1.73 m2 or an albumin-creatinine ratio ≥30 mg/g at the baseline visit.